Cargando…

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis

INTRODUCTION: Telaprevir (TVR) plus peg interferon (PEG-IFN) and ribavirin (RBV) substantially increase treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection but data about its safety in HIV patients with cirrhosis are lacking. Our purpose was to evaluate estimated Glomerular F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puzzolante, Cinzia, Vecchia, Marco, Zona, Stefano, Borghi, Vanni, Guaraldi, Giovanni, Mussini, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P095
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224941/ https://www.ncbi.nlm.nih.gov/pubmed/25394131 http://dx.doi.org/10.7448/IAS.17.4.19627

Ejemplares similares

Implementation of virtual consultations within an acute MSK Physiotherapy Paediatric service, in response to the Covid-19 pandemic – Patient/parent feedback
por: Webster, C., et al.
Publicado: (2022)

Développement d’une méthode d’imagerie multiplexée de la peau : application aux lésions cutanées contemporaines de la COVID-19
por: Tauber, Marie, et al.
Publicado: (2021)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk
por: Menozzi, Marianna, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Burden of subclinical heart and lung disease detected on thoracic CT scans of HIV patients on HAART
por: Zona, Stefano, et al.
Publicado: (2014)

Predictors of emphysema progression in HIV-positive patients
por: Guaraldi, Giovanni, et al.
Publicado: (2014)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Evaluation of the degree of liver fibrosis and genetical characteristics in HIV patients with spontaneous clearance of HCV in Cartagena, Spain
por: Jesús Vera Méndez, Francisco, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Risk of liver decompensation assessed in HIV/HCV co-infected individuals with advanced liver fibrosis: a faster countdown experience
por: Pedro Alves, Joao, et al.
Publicado: (2014)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir
por: Aghemo, Alessio, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients
por: Brogueira, Pedro, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
por: Lonardo, Amedeo, et al.
Publicado: (2016)

Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users
por: Oprea, Cristiana, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

The Impact of COVID-19 on UNAIDS 90–90–90 Targets: Calls for New HIV Care Models
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program
por: Calvaruso, Vincenza, et al.
Publicado: (2019)

Incidence of recent HCV infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan
por: Su, Yi-Ching, et al.
Publicado: (2014)

Plasmacytoid Dendritic cells (pDCs) in HIV-infected and HIV/HCV-co-infected patients receiving successful treatment
por: Khokhlova, Olga, et al.
Publicado: (2014)

Adherence to Lipid-Lowering Medication in People Living with HIV: An Outpatient Clinic Drug Direct Distribution Experience
por: Cuomo, Gianluca, et al.
Publicado: (2021)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

Implementation of hcv screening in the 1969-1989 birth-cohort undergoing covid-19 vaccination: a pivotal study in Italy
por: D'Ambrosio, R., et al.
Publicado: (2022)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bkqnmteu8jam41g5b4o7tahf0u